Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis

References

• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):1–7. doi: 10.1016/j.jaad.2013.10.010.
   Web of Science ®Google Scholar
• Nomura T, Honda T, Kabashima K. Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers. Int Immunol. 2018;30(9):419–428. doi: 10.1093/intimm/dxy015.
   PubMed Web of Science ®Google Scholar
• Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192–199. doi: 10.1111/j.1525-1470.2005.22303.x.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4s):S65–s76. doi: 10.1016/j.jaci.2017.01.011.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z.
   PubMed Web of Science ®Google Scholar
• Howell MD, Kuo FI, Smith PA. Targeting the janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342. doi: 10.3389/fimmu.2019.02342.
   PubMed Web of Science ®Google Scholar
• Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783–798. doi: 10.1007/s40257-020-00548-6.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158–1167. doi: 10.1111/1346-8138.16549.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023;34(1):2212095.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869–879. doi: 10.1111/1346-8138.16763.
   PubMed Web of Science ®Google Scholar
• Hagino T, Yoshida M, Hamada R, et al. Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate-to-severe atopic dermatitis. J Dermatol. 2023;50(12):1576–1584. doi: 10.1111/1346-8138.16950.
   PubMed Web of Science ®Google Scholar
• Hagino T, Hamada R, Yoshida M, et al. Effectiveness and safety of upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol. 2023;16:3201–3212. doi: 10.2147/CCID.S439053.
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Optimal use of jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence. JID Innov. 2023;3(3):100195. doi: 10.1016/j.xjidi.2023.100195.
   PubMedGoogle Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib. J Dermatol. 2023;50(10):1301–1312. doi: 10.1111/1346-8138.16879.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Ortoncelli M, Schena D, et al. Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation. Am J Clin Dermatol. 2023;24(6):953–961. doi: 10.1007/s40257-023-00798-0.
   PubMed Web of Science ®Google Scholar
• Kosaka K, Uchiyama A, Ishikawa M, et al. Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-Centre retrospective study. Eur J Dermatol. 2022;32(6):800–802. doi: 10.1684/ejd.2022.4365.
   PubMed Web of Science ®Google Scholar
• Tran V, Ross G. A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis. Australas J Dermatol. 2023;64(4):e352–e356.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Thaçi D, Bieber T, et al. Upadacitinib for moderate-to-severe atopic dermatitis: stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023;37(9):1871–1880. doi: 10.1111/jdv.19232.
   PubMedGoogle Scholar
• Hagino T, Yoshida M, Hamada R, et al. Early itch relief with upadacitinib predicts later skin clearance in atopic dermatitis. J Dermatolog Treat. 2024;35(1):2291317.
   PubMed Web of Science ®Google Scholar
• Hagino T, Yoshida M, Hamada R, et al. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J Dermatolog Treat. 2023;34(1):2276043.
   PubMed Web of Science ®Google Scholar
• Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448–458. doi: 10.1016/j.alit.2022.06.009.
   PubMed Web of Science ®Google Scholar
• Nomura T, Kabashima K. Advances in atopic dermatitis in 2019-2020: endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cells. J Allergy Clin Immunol. 2021;148(6):1451–1462. doi: 10.1016/j.jaci.2021.10.022.
   PubMed Web of Science ®Google Scholar
• Zhou L, Leonard A, Pavel AB, et al. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2019;144(1):144–156. doi: 10.1016/j.jaci.2019.01.015.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The eosinophil-to-lymphocyte ratio acts as an indicator for improvement of clinical signs and itch by upadacitinib treatment in atopic dermatitis. J Clin Med. 2023;12(6):2201. doi: 10.3390/jcm12062201.
   PubMed Web of Science ®Google Scholar